Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
October 16, 2024 6:50 AM EDTRBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $181.00 (from $178.00) while maintaining a Outperform rating.
The analyst comments "JNJ delivered a Q3 beat on sales/EPS that sent the stock up ~2% today. The company delivered +5.6% y/y underlying... More
Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
October 15, 2024 2:22 PM EDTStifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $160.00) while maintaining a Hold rating.
The analyst comments "Helped by better-than-expected 3Q24 Pharmaceutical division performance, both JNJ 3Q24 sales and EPS outperformed Stifel and consensus. And looking ahead, the company's... More
Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
October 15, 2024 8:20 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $180.00 price target on Johnson & Johnson (NYSE: JNJ).
The analyst comments "JNJ delivered 3Q24 revenue of $22.5B (up 5.6% organic) ahead of consensuss $22.2B. Innovative Medicine sales were $14.58B (up 6.7% organic ex-Covid-19, versus consensuss... More

